Abstract: As a result of the COVID-19 pandemic, various joint efforts have been made to support the creation of vaccines. Different projects have been under development, of which some are in the clinical evaluation stage and others in are in phase III with positive results. The aim of this paper was to describe the current situation of the development and production of vaccines available to the population to facilitate future research and continue developing and proposing ideas for the benefit of the population. So, we carried out a systematic review using databases such as PubMed, ScienceDirect, SciELO, and MEDLINE, including keywords such as “vaccines,” “COVID-19,” and “SARS-CoV-2”. We reviewed the development and production of the anti-COVID vaccine and its different platforms, the background leading to the massive development of these substances, and the most basic immune aspects for a better understanding of their physiological activity and the immune response in those who receive the vaccine. We also analyzed immunization effects in populations with any medical or physiological conditions (such as immunosuppression, people with comorbidities, and pregnancy), as well as the response to immunization with heterologous vaccines and the hybrid immunity (the combination of natural immunity to SARS-CoV-2 with immunity generated by the vaccine). Likewise, we address the current situation in Mexico and its role in managing the vaccination process against SARS-CoV-2 at the national and international levels. There are still many clinical and molecular aspects to be described, such as the duration of active immunity and the development of immunological memory, to mention some of the most important ones. However, due to the short time since the global vaccination roll-out and that it has been progressive (not counting children and people with medical conditions), it is premature to say whether a second vaccination schedule will be necessary for the near future. Thus, it is essential to continue with health measures.

Keywords: SARS-CoV-2; COVID-19; vaccines; immunity; efficacy; humoral immunity; cellular immunity

1. Introduction

Until recently, the coronavirus family was not considered highly contagious. Human coronaviruses, such as HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, are very common and usually cause colds like other pathogens but have low immunogenicity [1]. However, since SARS-CoV appeared in 2002–2003 and MERS-CoV in 2012, health authorities worldwide began to pay attention to the behavior and dispersal of these genotypes. As a result, various research lines emerged to understand better their pathogenicity and immunogenic capacity [2].

At the end of 2019, a new disease was announced caused by a viral agent belonging to the coronavirus family. It was named SARS-CoV-2 due to its relationship with the virus that...
causes Severe Acute Respiratory Syndrome (SARS) and the infection mechanism is relies on the protein “S”, which is composed of two subunits, S1, which contains the receptor-binding domains that recognizes and binds to the host receptor angiotensin-converting enzyme 2 (ACE-2), and subunit S2, which mediates viral cell membrane fusion [3]. Its infection causes the disease COVID-19, an acronym for coronavirus disease with the year it was discovered. The first registered case occurred in Wuhan, China, on 31 December 2019 [4]. Shortly afterward, the World Health Organization (WHO) declared a pandemic due to the rapid spread of this new virus worldwide, affecting thousands of people. As a result of this pandemic, various joint efforts have been made to support the creation of vaccines. At least 300 projects have been reported under development, of which 40 are in clinical evaluation and 10 in phase III with positive results. In addition, to prevent the spread of the virus and protect the population, the WHO has licensed at least five vaccines for emergency use [5].

2. Methodology

A literature review about vaccines against COVID-19 was carried out. The databases used in the search were Scopus, PubMed, ScienceDirect, MEDLINE, and SciELO. The search was performed on each database using a combination of the following keywords: “vaccines,” “SARS-CoV-2,” and “COVID-19”. As inclusion criteria, only references with full text in English or Spanish were considered. The titles and abstracts of the references were reviewed as exclusion criteria to assess their coherence with the search topic, and unrelated articles were dismissed.

3. COVID-19 Vaccines Development

Developing a vaccine is a complex process that can take up to 8 years before being available to the population. In addition, strict protocols must be followed to guarantee its safety and efficacy. However, for COVID-19, it was completely different. There is a 79.5% genetic similarity between SARS-CoV and SARS-CoV-2 [6]. Thus, the previous knowledge gathered from the first investigations on this virus family that began almost two decades ago proved to be relevant for developing vaccines against SARS-CoV-2 and, of course, producing them in record time. Additionally, the contributions of Katalin Karikó regarding the use of modified mRNA as a tool for immunological purposes [7] allowed the global pharmaceutical industry to start producing these vaccines. A brief scheme of the entire vaccine development process and COVID-19 vaccine is shown in Figure 1.

The development of the different types of vaccines shows the immense technological advances that exist today (Table 1). However, like any tool, they have advantages and disadvantages (Table 2) that must be pondered before choosing the most appropriate one. Moreover, vaccines can also enhance the immune response with the help of substances called adjuvants.

| Type of Vaccine | Development | Invention Year | Target Disease |
|-----------------|-------------|----------------|----------------|
| Attenuated pathogen | Through physicochemical treatments, the pathogen loses features that allow an effective infection. Due to the intact antigens on the membrane surface, they can be recognized by the immune system. | 1798 | Smallpox |
| Dead/inactivated pathogen | Through physicochemical treatments, the bacterial pathogen is killed and viral pathogen is inactivated. It cannot infect, but the antigens must remain on the membrane to be recognized by the immune system. | 1896 | Typhoid |
| Toxoids | The bacterial toxins are attenuated with chemical agents such as formaldehyde or the effects of heat, preserving their high immunogenicity. | 1923 | Diphtheria |
Table 1. Cont.

| Type of Vaccine | Development | Invention Year | Target Disease |
|-----------------|-------------|----------------|----------------|
| Protein subunits| They contain only harmless proteins of the microorganism. They are made by recombinant expression in cell models such as bacteria or fungi, or obtained by lysis of the pathogen, but the proteins that join to the host’s receptors are preserved to protect their three-dimensional conformation. The structural proteins of the pathogen are assembled using a matrix (which can be a lipid bilayer) which allows simulating the pathogen’s spatial conformation without genetic content. They have high immunogenicity since most of the pathogen’s proteins are present. These are genetically modified viruses, which have already been well characterized. The genetic content is eliminated, except for those genes that give a cell the ability to infect. The removed genetic material is replaced by that that is of interest (DNA or mRNA *) and incorporated into the virus for protection and transport. Once the vector comes into contact with human cells, it instructs them to produce a protein exclusive for the microorganism. Thus, the body begins to manufacture components of the immune system. Most of these viral vectors cannot replicate. They can be DNA or mRNA. In both cases, the genetic material is protected by a nanoparticle, mainly lipids, since it becomes permeable to the phospholipid bilayer of the cell membrane. DNA travels through the cytosol until incorporated into the nucleus, where it is transcribed into mRNA and later translated into a chain of amino acids. Something similar happens with the mRNA, but it does not enter the nucleus, instead passing directly to the ribosomes to synthesize the chain of amino acids. Finally, this genetic material allows the production of pathogenic proteins which will be expressed at the membrane surface level, thus achieving the creation of antigens through our cells, which will stimulate the immune system. | 1970 | Anthrax |
| Viral particles | | 1986 | Hepatitis B |
| Viral Vectors | | 2019 | Ebola |
| Nucleic acids | | 2020 | SARS-CoV-2 |

Refs. [8,9]; * DNA: Deoxyribonucleic acid; mRNA: Messenger-type ribonucleic acid.

Table 2. Advantages and disadvantages of different platforms for vaccine development.

| Platform | Advantages | Disadvantages |
|----------|------------|---------------|
| Attenuated pathogen | Produces humoral and cellular response with a single dose. | Safety problems in immunosuppressed people. Strains are difficult to obtain. |
| Dead/inactivated pathogen | Safe due to the nature of its composition. Very easy to transport and store. | Large amounts of the pathogen. Possible effects on the immunogenicity of the antigen |
| Protein subunits | Safe during production and for immunosuppressed people. | Decrease in APC * capacity due to particle size. Limited production due to product scalability. There is only IgM production. Low memory immunity. Low efficiency in children. |
| Polysaccharides | Alternative against bacteria with abundant polysaccharide antigens. | |
| Viral particles | Combines the efficacy of live and subunit vaccines. High scalability production. | Particle assembly is a complex process. |
| Viral Vectors | It can induce a humoral and cellular response. Safe. | Pre-existing immunity is used against the vector. It needs low temperatures to store. |
| Nucleic acid | Rapid design and development. Scalability. Very secure. Induces humoral and cellular responses. | Its storage and handling are delicate. |

Refs. [5,10]; * APC: Antigen presenting cell.
Adjuvants

Aluminum salts as adjuvants have been used in different vaccines, such as the PiCoV-acc and CoV-RBD219N1 vaccines for the SARS-CoV-2 virus, promoting higher antibody production [13]. The Novavax vaccine uses Matrix-M1 as an adjuvant, based on purified saponin obtained from the Quillaja saponaria tree, formulated with cholesterol nanoparticles and phospholipids [14]. This adjuvant enhances the immune response by recruiting a larger amount of APC at the application site, which increases the presentation of antigens to T cells, generating a TH1 and TH2 response [15]. In addition, it induces antibodies of multiple subclasses, mainly high titers of anti-S IgG that block the binding of the ACE2 receptor, neutralizing the virus, reducing the dose of antigen used in each vaccine, and reducing costs [16]. SARS-CoV-2 vaccines formulated with soluble homogeneous “Spike” protein S trimers (S-2P) use AS03 as an adjuvant, an oil-in-water emulsion composed of squalene, polysorbate 80, and α-tocopherol. This compound induces an IgG antibody response sufficient to protect from exposure to SARS-CoV-2 [17]. The Sclamp vaccine, which is in the preclinical stage, consists of stabilized recombinant viral “Spike” glycoprotein S in its trimeric form used in combination with the MF59 adjuvant, which consists of a 4.3% squalene oil emulsion in water, stabilized with Tween 80 and Span 85. This adjuvant interacts with the APCs at the inoculation site and participates in the transfer of antigens, increasing the efficiency of antigen presentation and stimulating a significant immune response mediated by neutralizing antibodies [18]. The CIGB2020 compound, produced by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, has been used to formulate vaccines against hepatitis. It stimulates specific genes to produce interferons and other cytokines with antiviral properties, which also intervene in the expression of class I and II human leukocyte antigen (HLA) molecules. These molecules are involved in the activation of the innate immune system and increase the presentation of viral antigens, and therefore, stimulate T cells [19]. In March 2020, clinical trials were initiated to explore
and evaluate the immunotherapeutic effect of this substance in suspected and confirmed patients with SARS-CoV-2 infection. However, the results of this protocol have not been published yet [20].

4. COVID-19 Vaccines

The available information about this coronavirus family was immensely advantageous compared to other cases since, as explained in Figure 1, the time required to formulate a vaccine is considerable. Tables 3 and 4 list the main vaccines currently available and those used since the beginning of 2021 in the global vaccination campaign to counteract the number of infections and victims of COVID-19 disease.

Table 3. Primary nucleic acid-based vaccines and viral vectors available for use in some regions of the world.

| Type of Vaccine | Nucleic Acids | Vector Viral |
|-----------------|--------------|--------------|
| Name            | Comirnaty (BNT162b2 mRNA) | AZD1222 (ChAdOx1) | Sputnik V (Gam-COVID-Vac) |
| Manufacturing Company | Pfizer/BioNTech | Moderna CureVac/Bayer/ GSK/No vartis | AstraZeneca/Oxford |
| Handling/ Storage | –70 °C up to 6 months, 2–8 °C up to 5 days, reconstituted up to 6 hrs | –20 °C up to 6 months, 2–8 °C up to 30 days | –2–8 °C |
| Doses required | Second dose 28 days after the first one | Second dose 28 days after the first one | Second dose 28 days after the first one |
| Immunization per dose | 30 μg (3rd doses) | 12 μg | 0.5 × 10^{11} Vp |
| % Efficacy in preventing infection | 95% | Phase III data to be published 82.4% | 65.28% |
| Observations | It contains a strand of mRNA that codes for the protein S “Spike” wrapped in a lipid nanoparticle using polyethylene glycol as a stabilizing agent. The third dose is being evaluated in patients 18–55 years and 65–85 years. | It contains a strand of mRNA that codes for the protein S “Spike” wrapped in a lipid nanoparticle. | Chimpanzee adenovirus containing mRNA encoding protein S “Spike.” |

EMA: European Medicines Agency; Vp: Viral particles; mRNA: Ribonucleic acid of the messenger type; DNA: Deoxyribonucleic Acid; * J & J Pharmaceuticals indicates that two doses may be required depending on the patient’s needs and the health care provider’s determination. They all contain the “S” gene in the form of mRNA or DNA [21–32].
Table 4. Primary vaccines based on the attenuated SARS-CoV-2 virus and protein “S” subunits available for use in some regions of the world.

| Characteristics | Attenuated Pathogen Name | Protein Subunits | Type of Vaccine |
|-----------------|--------------------------|------------------|-----------------|
| Type of Vaccine | CoronaVac (BBV152 A, B, C) | Not Available | Sinovac |
| Characteristics | Bharat Biotech/Indian Council of Medical Research | Sinopharm/Wuhan Institute of Biological Products | Sinopharm/Beijing Institute of Biological Products |
| Manufacturing Company/Institution | NOVAVAX | Anhui Zhifei Longcom Biopharmaceutical Co./Government of Uzbekistan |
| Handling/Storage | 2–8 °C Second dose 14 days after the first one | 2–8 °C Second dose 21 days after the first one | 2–8 °C Second dose 21 days after the first one |
| Doses required | Second doses 28 days after the first one | Second dose 21 days after the first one | Second dose 21 days after the first one |
| Immunization per dose | 3 µg | Unknown | 4 µg |
| % Efficacy in preventing infection | 83.7% in Turkey | 81% | 72.5% |
| | 50.3% in Brazil | | 79.34% |
| Observations | Nanoparticles containing the protein subunit S. | Recombinant origin using CHO cell line to express protein S. | |

CHO: Chinese Hamster Ovary; Adjuvant: A molecule that helps increase the immune response; B.1.1.7: British variant; B.1.351: South African variant [16,24,33–36].

Most of these vaccines have been approved by the WHO with an “emergency” use license; that is, these are vaccines that present conclusive data regarding the level of conferred protection, safety, and efficacy when monitoring the population selected for the clinical trials for at least two months [37]. However, on 23 August 2021, and 31 January 2022, the FDA approved with a full license the use of Pfizer/BioNTech and MODERNA vaccines, respectively [38,39]. It also must be considered that public and private investments, which are unprecedented events, allowed the great researchers of the 21st century to act immediately to develop these vaccines. Unfortunately, some of these products have encountered problems during application in various regions. The first complication occurred with the Pfizer/BioNTech vaccine. A case was reported of a person who developed an exacerbated allergy to one of the primary vaccine compounds, polyethylene glycol, an allergenic molecule for certain people. Therefore, it is recommended to conduct a comprehensive review of the patients’ medical history to detect any known allergies [22]. On the other hand, after receiving the Astra Zeneca/Oxford vaccine, the presence of blood clots that caused either thrombosis or thrombocytopenia was reported in certain patients. This incident led some countries to suspend vaccination with this vaccine, even though 20 million doses had already been applied. Shortly after, on 19 March 2021, the WHO made a public statement in conjunction with the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) regarding these events. The statement read that all adverse events had been carefully analyzed and that pondering the number of vaccine doses already applied, the number of reported cases was not relevant to conclude that the vaccine was unsafe. Additionally, the number of reports was within the permissible limits for these very rare events. Finally, they stressed that the benefits provided by the vaccine were more significant than the possible side effects that may arise and that it is essential to assess the clinical conditions of each patient for these events [40].
Still, many other projects are in the early stages despite financing issues and specialized human resources needs. These enterprises will undoubtedly promise a very competitive market, in which purchasing power will not be a problem for less developed countries as there will be an extensive manufacturer catalog [41].

4.1. Dose Immunization

Viral vector and nucleic acid vaccines require the application of two doses. The reason why this vaccination scheme is needed is that the immune system works in two ways. The first time there is contact with a pathogen, nonspecific IgM-type antibodies are produced (Figure 2A) that will help to block the pathogen during the primary response, which begins within three to five days. Then, highly specific and low-molecular-weight IgG-type antibodies (Figure 2B) are produced 10 to 15 days later. This adaptive response can last weeks and even months [42] (Figure 3). Because it is a parenteral type of immunity, the production of these immunoglobulins in the bloodstream is stimulated to avoid possible damage at the systemic level [43], along with a small synthesis of IgA immunoglobulins.

![Figure 2.](image-url)

Figure 2. (A) Production of IgM antibodies after the first dose. Although there is a considerable quantity of immunoglobulins, their ability to neutralize SARS-CoV-2 is limited due to their size. Additionally, being very heavy, they cannot easily cross the capillary alveolus barrier due to the significant variability in their antigen-binding fragments (Fab). (B) IgM and IgG antibodies coexist. The latter are more specific and capable of neutralizing SARS-CoV-2. Due to their lower molecular weight, they manage to cross the capillary alveolus barrier. However, this does not mean that infection cannot occur; it only decreases the risk of developing COVID-19. Therefore, it is necessary to continue with adequate sanitary measures. Design by Carlos U. Torres-Estrella.
The genetic material contained in the vaccine is limited to the number of copies supplied to the person receiving it. Not all will translate into a protein, as some will degrade due to vesicular trafficking. Thus, a second dose ensures that the adaptive response is activated more efficiently and that the number of translated proteins is enough for a response. However, this is not strong enough to keep immune levels up. Due to the fact that the immune response decreases, a third dose is necessary to maintain the protection (Figure 3) according to the Center for Disease Control and Prevention (CDC) and the Johns Hopkins medical school [44,45].

4.2. Heterologous Vaccines

It is known that booster immunization with heterologous vaccines can increase the intensity and amplitude of immune responses. Therefore, in the face of the current pandemic caused by the SARS-CoV-2 virus, heterologous vaccines against COVID-19 have emerged as a valuable alternative to provide the necessary immunological protection to the affected population. He et al. [47] conducted a study aimed at maximizing the benefits of vaccination using a heterologous booster strategy in a murine model, applying different combinations of four types of leading candidate vaccines against COVID-19 that were found in clinical trials in China. Their results showed that sequential immunization with an adenovirus-vectored vaccine followed by administering an inactivated/recombinant subunit/mRNA vaccine specifically increased neutralizing antibody levels and promoted the modulation of immune response antibodies to predominantly neutralizing antibodies. In addition, the heterologous priming and boosting regimen with an adenovirus vector-based
vaccine also enhanced Th1-biased T cell responses. Thus, their results provided new ideas for developing and applying COVID-19 vaccines to control the SARS-CoV-2 pandemic.

Likewise, a study conducted by Hillus et al. [48], evaluated the reactogenicity and immunogenicity of heterologous immunizations with ChAdOx1 nCov-19 (AstraZeneca, Cambridge, UK) and BNT162b2 (Pfizer-BioNTech, Mainz, Germany), in comparison with homologous immunization with BNT162b2 and ChAdOx1 nCov-19. The study showed evidence of the safety and immunogenicity of heterologous ChAdOx1 nCov-19-BNT162b2 vaccination, currently recommended in several countries. Thus, their data support ongoing efforts to investigate heterologous vaccination regimens for COVID-19.

On the other hand, Eroglu et al. [49] mentioned that the preliminary results of a trial with CombiVacS that included more than 600 patients in Spain showed the benefits of mixing different vaccines against coronavirus. In addition, they mentioned that the combination of the Oxford–AstraZeneca vaccine and the Pfizer–BioNTech vaccine also induced a stronger immune response than two doses of the same vaccine. However, they emphasized that it is essential to consider that some safety concerns remain when two different vaccines are combined as each vaccine has its own set of adverse events/side effects. Nevertheless, no severe side effects were reported in the combined trials.

5. Humoral and Cellular Immunity Generated by Vaccines

As already mentioned, the objective of vaccines is to achieve an effective and risk-free immunization without clinical complications, except for the common side effects (fever, pain, inflammation in the injection site, and headache). However, rare side effects are reported and investigated immediately [50]. Table 5 briefly shows the immunological characteristics acquired after SARS-CoV-2 vaccination. Although there are unreported data due to the clinical stage of some projects, it is observed that the majority fulfill the task of generating immunity and conferring protection to patients. Regarding mucosal-associated immunity, it is known that parenteral immunization can induce a response on this surface. Additionally, some vaccines stimulate the migration of T and B cells to these compartments [51], although this is not the case for SARS-CoV-2 vaccines. However, a substantial proportion of IgG antibodies against protein S and its RBD (Receptor Binding Domain) and IgA antibodies were reported in saliva samples of 45 healthcare workers after receiving the second dose of the Pfizer and Moderna vaccines [52]. It was also described that the reactivity of IgA and IgG antibodies in saliva and serum, as well as IgM, increased rapidly after vaccination in two people who had already contracted COVID-19. However, studies have not yet been conducted to quantify the production of immunoglobulins in the mucosa nor its duration.

5.1. Pregnant Women and Vaccination against COVID-19

A report was published recently on a small number of pregnant women (35,691 participants) between the ages of 16 and 54 who received the COVID-19 mRNA vaccine. The women experienced many typical side effects of a vaccine immunization, such as headaches, myalgias, chills, and fever. However, none presented any clinical alteration of greater risk. Pain at the injection site was also reported more frequently in pregnant women than in those who are not pregnant [53]. However, more extensive clinical trials to support these facts are not ruled out. In addition, it must be kept in mind that each woman evolves differently during pregnancy, so it is essential to evaluate the patient’s current health condition upon vaccination.
Table 5. Data reported on humoral and cellular immunity generated by vaccines administered so far to the population worldwide.

| Vaccine                      | Maximum Antibodies                                                                 | Type of Immunity Reported                                                                 | Detection Method         |
|------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------|
| RNm-1273 NIAID Moderna       | Antibodies have been reported six months after vaccination                         | CD4 + T H1 cells (TNF-α > IL-2 > IFN-γ), low expression of TH2 cytokines (IL-4 and IL-13) and detectable CD8 + T cell responses | ELISA                    |
| NT162b1 Pfizer/BioNTech      | Antibody rise 14 days after the booster dose                                        | Concurrent production of neutralizing antibodies, activation of CD4 + T lymphocytes biased to TH1 with little response of TH2 (IL-4) and CD8+, virus-specific, and the solid release of immunomodulatory cytokines such as IFN-γ. | Flow cytometry, IFNγ     |
| CanSino                      | IgG antibodies at 28 days. Neutralizing antibodies at 8 weeks.                     | CD4 + and CD8 + T cells produced IFN-γ, TNF-α, and IL-2, with a large proportion of both subsets of T cells being unique IFN-γ producers. Strong IgG1 and IgG2 responses. | ELISA IgG NAb by virus-specific microneutralization |
| ChAdOx1 CoV-19/AZD1222       | T-cell response from day 7, peaking on day 14 and remaining detectable until day 56. The last analysis detected IgG being at its peak on day 28 and remaining until day 56. IgG anti-S: 31/32 days after one dose. Neutralizing antibodies: 21–28 days after the first dose. | CD4 T + predominantly secreted Th1 cytokines (IFN-γ, IL-2, and TNF-α) rather than Th2 (IL-5 and IL-13). | Detection by IFN-γ ELISPOT assay before and after vaccination and flow cytometry. |
| VX-CoV237 (Novavax)          | IgG anti-S: Titters increased 1 to 35-fold within ten days after second dose immunization. | Induced CD4 + and CD8 + T cell response. | ELISA                    |
| 26.COV2.S Janssen/Johnson & Johnson | The first dose showed neutralizing antibodies on days 57 and 71. The second dose showed an increase in neutralizing antibody titers at day 57 | Central memory CD27 +/CD45RA−/CD4 + and CD8 + T cell response. Biased TH1 cellular immune response. | LISA, ELISPOT, and IFN-γ assays for cellular immune response. Intracellular cytokine staining for CD4 + and CD8 + T cells. |

ELISPOT: Enzyme-Linked Dot Immunoadsorption Assay; ELISA: Enzyme-Linked Immunosorbent Assay; NAb: Neutralizing antibodies; [21,23,25,26,28–32].

5.2. Population with Medical Conditions and COVID-19 Vaccination

The COVID-19 vaccine can be administered to people under medical treatment that does not contraindicate to vaccination. Patients with comorbidities can proceed with immunization [54], and receive any of the above vaccines. However, people with a medical condition such as immunosuppression or an autoimmune disease must consider certain factors, although there are still no sufficient clinical data on this population on their evolution after receiving the COVID-19 vaccine. According to CDC, immunosuppressed people can receive the COVID-19 vaccine since the clinical trials included HIV patients with immunosuppressive conditions. Although data from this population are not yet sufficient, they are supported by the "general practices for the vaccination of the immunocompromised population", which also apply to people receiving immunosuppressive therapy such as chemotherapy. The only condition is that the vaccination schedule must be completed at least two weeks before starting treatment. Individuals with advanced conditions can receive the vaccine if they undergo a medical assessment that includes the type of vacc-
cine, immunosuppression levels, the time it will last, and any comorbidities [55]. On the other hand, patients undergoing dialysis have shown greater immunogenicity with the MODERNA vaccine, up to 12 weeks after second dose vaccination [56].

5.3. Hybrid Immunity

In June 2020, it was revealed that the SARS-CoV-2 virus began to generate mutations, allowing it to evade neutralizing antibodies and become more infectious. Some of the mutant viruses that completely replaced the original SARS-CoV-2 were B.1.1.7 (Alpha), B.1.351 (Beta), B.1.1.248 (Gamma), and B.1.617.2 (Delta), which were called variants of interest (VOC) [57]. Among these, the Delta variant is the one that is spreading throughout the world. The presence of mutations in most VOC results in partial escape from antibodies. This biological process is evidence of selection pressure to evade natural immunity. A reduced neutralization potential of the antibodies against variants has been observed in the ChAdOx1 nCoV-19 vaccine (AstraZeneca, Cambridge, UK) against symptomatic patients. It was observed that the efficacy decreased from 75% to 11% against variant B.1.351 [58]. The BNT162b2 vaccine (Pfizer-BioNTech, Mainz, Germany) efficacy against symptomatic cases of the B.1.351 variant fell from ~95% to 75%, and protection in severely ill patients remained at 97% [59]. Likewise, it has been observed that both vaccines retain most of their efficacy against the B.1.617.2 (Delta) variant. Due to the reduction in neutralizing antibodies, the B cells recognize the mutated spike proteins of the variants. Studies of natural infection with B.1.351 have shown that the B cells recognize the mutated spike proteins of this variant since the responses of neutralizing antibodies were robust against that variant and the ancestral strain [60]. Therefore, it is crucial to understand the immune response mechanisms to vaccination. On the other hand, several researchers have shown that the vaccination of people convalescing from COVID-19 can produce neutralizing antibodies that can be up to a thousand times higher than those induced by infection or vaccination, suggesting that a way to control the pandemic may be the induction of hybrid immunity [61–65]. This type of immunity results from a combination of natural immunity and immunity generated by the vaccine. A greater than expected immune response arises when innate immunity to SARS-CoV-2 is combined with vaccine-induced immunity. “Hybrid immunity” is particularly interesting because people with prior SARS-CoV-2 infection develop unexpectedly strong immune responses to vaccines [61,66]. The latter is because memory B cells have two functions: one is to produce clonal antibodies after reinfection with the same virus, and the other is to encode a library of antibody mutations to protect themselves from viral variants that may emerge in the future. Thus, a substantial proportion of memory B cells encode antibodies capable of binding or neutralizing VOC, and the quality of those memory B cells increases over time [64,65].

Additionally, Andreano et al. [67] analyzed the repertoire of B cells that produce neutralizing antibodies after vaccination with BNT162b2 mRNA in healthy individuals not previously infected with SARS-CoV-2 and people with prior exposure to SARS-CoV-2. Subjects with previous SARS-CoV-2 infection responded to vaccination with a higher number of antibody-producing B cells not susceptible to variants of interest and with higher neutralizing power. The latter may be partly explained by the increased number of somatic mutations and the fact that seropositive individuals shed antibodies potent germline-derived IGHV2-5 and IGHJ4-1 antibodies, which were not observed in healthy vaccinated subjects [65]. Thus, it is suggested that the third dose of this vaccine could lead to a response similar to hybrid immunity since neutralizing antibodies after infection and vaccination are mainly derived from the same immunodominant germ lines [68].

6. Immunization Alternatives

Routes of mucosal immunization, such as intranasal and oral, are constantly being studied. However, their application in clinical practice has been limited due to the technical and safety challenges they pose. Most currently approved human vaccines are administered
systemically, e.g., intramuscular and subcutaneous. Although these pathways can elicit systemic humoral immune responses and are regulated by antigen-specific cells, they are generally incapable of producing IgA responses and mucosal protective immunity. The mucosal pathway of immunization causes immune responses at the local and distal mucosal sites and systemic immune responses. Therefore, most current efforts to obtain mucosal protective immunity have focused on mucosal vaccination routes, such as oral and intranasal [69]. Although the induction of a mucosal response by systemic immunization remains poorly understood, in recent studies, the existence of neutralizing antibodies against SARS-CoV-2 in saliva, the pharynx, and the nose has been shown using swabs to collect the samples [70]. Therefore, using an appropriate adjuvant could change the outcome and lead to IgA expression [71]. Currently, intranasal vaccines against SARS-CoV-2 are being developed (Figure 4) but are still in the preclinical study stage. However, it has been observed that they can generate certain immunity in the mucosa since there is a production of IgA antibodies, which bind SARS-CoV-2 RBD with high affinity, involving interaction with the ACE2 receptor [72].

Figure 4. Representation of intranasal immunization, in which a higher production of immunoglobulin IgA is prompted. However, this protein does not remain active for long periods. Design by Thalía F. Camarillo González and Valeria Juárez-García.

7. Mexico and Vaccination against COVID-19

In Mexico, the lethality rate for COVID-19 in 2021 was 8.7, which places the country in first place worldwide on this indicator [73]. However, it is expected that these figures will decrease as the vaccination campaign progresses. So far, 80 million doses have been administered, with only 70 million people fully vaccinated as of January 2022, equaling 60.62% of the total population [74].
Given that the current demand for vaccines is extremely high, some pharmaceutical companies, such as Pfizer-BioNTech (Mainz, Germany), have not been able to supply all the orders requested by the various countries, including Mexico. Therefore, they have found themselves needing to open new manufacturing sites to achieve a successful supply [75]. Likewise, Mexico has ventured into performing some parts of the manufacturing process locally to counteract the shortage. Such is the case for the Astra Zeneca [76] and CanSino Biologics vaccines, in which the packaging is performed locally to benefit the population from gaining access more quickly [77,78].

On the other hand, Mexico has decided to develop its vaccine. Four projects are known to be under development (Table 6), which were presented to the Coalition for Innovations in Preparedness for Epidemics (CEPI). Although they are still undergoing preclinical evaluation, it is expected that they will reach phase III with promising results. This enterprise will allow the country to enter a very competitive market niche and demonstrate its great scientific capacity.

| Institution/Company | Financing                        | Type of Vaccine                                      |
|---------------------|----------------------------------|------------------------------------------------------|
| Avimex®, Universidad Nacional Autónoma de México and Instituto Mexicano del Seguro Social. Institutte de Biotecnología, Universidad Nacional Autónoma de México. Universidad Autónoma de Querétaro and Instituto Politécnico Nacional. Universidad Autónoma de Baja California and Tecnológico de Monterrey. | AMEXCID, CONACyT and SECTEI | Viral vector with nucleic acids. Veterinary platform. |
|                     |                                  | AMEXCID, CONACyT and SECTEI | Viral vector                                    |
|                     |                                  | AMEXCID, CONACyT and SECTEI | Viral vector                                    |
|                     |                                  | AMEXCID, CONACyT and SECTEI | Synthetic nanoparticle                           |

Table 6. Leading companies/institutions developing projects to produce a COVID-19/vaccine in Mexico.

AMEXCID: Agencia Mexicana de Cooperación Internacional para el Desarrollo, CONACyT: Consejo Nacional de Ciencia y Tecnología, SECTEI: Secretaria de Educación, Ciencia, Tecnología e Innovación.

Of all projects, the one with the greatest potential is the one that Avimex® will produce. This vaccine will use the technology developed by the Icahn School of Medicine at Mount Sinai in New York City and the University of North Carolina at Chapel Hill. Their experiments focused on the expression of protein S in chicken embryos using the Newcastle virus as a viral vector [79]. This laid the foundations to scale the production of this vaccine and partner with Avimex®. This company has over a decade of experience producing drugs for veterinary use and even a vaccine against the A(H1N1) pandemic influenza virus [80].

8. Discussion

Vaccination against SARS-CoV-2 has been an important tool to protect the population, including children 12–15 years old, from severe illness and long-term complications However, vaccination in children under 12 years old has been controversial because, although there are multiple benefits, there are also potential risks [81]. Recently, a clinical study evaluated two mRNA vaccines against SARS-CoV-2 in children younger than 12 years of age showing the safety, immunogenicity, and efficacy of vaccination in this pediatric population [82]. So, in a short time, the entire pediatric population may be vaccinated.

The introduction of vaccines is just a step forward to ending the current pandemic. We must not fail to follow the prevention measures established by the CDC, which include wearing protective glasses and masks and constant handwashing, among others. Additionally, it is vital to implement new strategies that reduce the exposure and contagion of the virus, such as nasal masks [83]. Along with the vaccination campaign, these measures will help counteract the virus’s spread until there is a sufficient availability of all vaccines. Likewise, it is necessary to obtain more data on the cellular immunity these vaccines induce and how rapidly they produce immunological memory since most data point to humoral immunity. The current data lead us to believe that, although current vaccines are being de-
veloped quickly, they confer a low level of immunogenicity, which is why a poor duration of cellular immunity has been seen.

On the other hand, the recently described variants pose a challenge for researchers as they may be more infectious [84], and very few vaccines have reported effectiveness against these mutations. Due to the above, vaccination schedules must be carefully analyzed to determine if a long-lasting and protective immunity is created or if booster doses, a combination of immunogens, or even annual vaccinations will be required. It also raises the question of whether these vaccines will be sufficient to counteract the spread of the virus and its new strains in the long term or if present platforms will need to be adjusted to provide an adequate immunogenic level. The latter does not mean that current platforms fail to fulfill their mission fully. However, being the first time in the history of medicine that these types of vaccines are used, it is necessary to make modifications to improve active immunity and guarantee that it is present in the majority of the population, including children and people with medical conditions. In this context, one component that can be added to vaccines to induce an immune response is adjuvants. The most important are aluminum salts, formulated with protein S, inducing neutralizing antibodies and protecting the body against SARS-CoV-2. However, various studies have shown that it cannot activate CD4+ T and CD8+ T cell responses.

On the other hand, the adjuvants based on emulsions (MF59, AS03), and the Toll-like receptor (TRL) agonists, unlike aluminum salts adjuvants, can provoke a more balanced immune response in protein-based vaccines. The previous is because they improve the antigen uptake and recruit immune cells, inducing both a humoral and a cellular response, which could be more beneficial [85,86]. Although various adjuvants have been used to formulate COVID-19 vaccines, more studies are required to achieve a combination of antigens and adjuvants that can provide a safer and more effective result. Likewise, another alternative to reduce exacerbated inflammation in patients could be the immunopotentiation of vaccines, or therapeutic vaccines, given when the individual is already infected. For instance, these vaccines are used for Human Papilloma Virus (HPV) to stimulate a better cellular response, mainly CD4+ and CD8+ lymphocytes [87], due to these immune cells’ natural low activation. Something similar happens with SARS-CoV-2 infection, raising the possibility of using these types of vaccines to promote a better response in the body.

On the other hand, an important issue is epigenetics. Even though no studies have delved into this issue yet, we believe that evaluating it is essential because of the variability in vaccine efficacy in different regions. Another factor to consider is the nutritional status of the individual. The main aim of vaccines is to achieve an effective, long-lasting, and protective immune response in the body, depending on various cells and molecules such as lymphocytes, antibodies, and cytokines. These cells require adequate energy sources, substrates, and nutrients, derived mainly from diet for their synthesis, development, and correct functioning [88].

The immune system needs energy-producing substrates to activate. Glucose and amino acids are required to generate cellular structures, fatty acids to produce lipid derivatives such as prostaglandins and leukotrienes, and vitamins and minerals serve as cofactors with an immunomodulatory effect. All these components are acquired through diet, which, if inadequate, cause an ineffective immune response to natural infection or induced by a vaccine [89].

Malnutrition favors an inadequate immune system response due to the lack of nutrients and substrates for the synthesis of immunological components. For instance, vitamin A intervenes in the maturation of T lymphocytes and the proliferation of CD8+ lymphocytes and B lymphocytes. Malnutrition can have two extremes that affect the immune response, malnutrition, and obesity. Obesity is an abnormal or excessive accumulation of adipose tissue, considered an endocrine organ, leading to a state of immunosuppression. Such a state is associated with the production of adipokines, mainly leptin, which under physiological conditions participate in the activation of neutrophils, proliferation of T cells, and cytokine synthesis. In obese individuals, high leptin levels induce a state of
resistance that reduces physiological activities. Other immunological alterations related to obesity are decreased circulating lymphocyte populations and the hyperactivation of the mTOR protein in immune cells, which favors an increased activation of effector cells, compromising memory lymphocytes production [90]. Therefore, this population needs to improve its eating habits since vulnerable individuals have some nutritional deficits, as seen throughout this pandemic.

However, we are aware of the immense effort that has been made over just one year. We acknowledge that this generational leap in vaccine development represents one of the most significant technological advances in medicine of the last decade. This breakthrough will support new immunization routes that better activate the immune response. We consider that one of these routes should be the mucous membranes, as it is the first route of contact with many pathogens, and it is necessary to neutralize them and avoid compromising the lower respiratory tract or decreasing its damage. Likewise, the United States government has requested to release the patent for vaccines against COVID-19 [91], which could enhance its development and upgrade. Additionally, pharmaceutical companies using the same platform will be able to conduct more detailed studies that allow the combination of vaccines, increasing the number of individuals with complete vaccination schedules in a shorter time. The previous also implies a boost in their production. Another option is to support projects that improve the immunogenicity of available vaccines and reduce the number of doses, achieve broader coverage, and above all, provide developing countries the opportunity for rapid access. In the meantime, we must not ignore the fact that detailed knowledge on these new technologies is still limited to many people, so it is necessary to take preventive measures that allow safe production and high-quality levels and standards.

**Author Contributions:** Conceptualization, G.A.-A. and C.U.T.-E.; writing—original draft preparation, G.A.-A., C.U.T.-E., M.d.R.R.-M., E.D.-E., M.S.M. and M.G.F.-D.-L.; writing—review and editing, G.A.-A., C.U.T.-E., M.d.R.R.-M., E.D.-E. and M.G.F.-D.-L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Los 7 Tipos de Coronavirus Que Infectan Humanos. Available online: https://www.nationalgeographic.com.es/ciencia/siete-tipos-coronavirus-que-infectan-humanos_15353 (accessed on 31 March 2021).
2. Cui, J.; Li, F.; Shi, Z.L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019, 17, 181–192. [CrossRef] [PubMed]
3. Huang, Y.; Yang, C.; Xu, X.; Feng, X.; Liu, W.; Wen, S. Structural and functional properties of SARS-CoV-2 spike protein: Potential antiviral drug development for COVID-19. Acta Pharmacol. Sin. 2020, 41, 1141–1149. [CrossRef] [PubMed]
4. Patrucco, F.; Gavelli, F.; Shi, R.; De Vita, N.; Pavot, A.; Castello, L.M.; Ravanini, P.; Balbo, P.E. Corona-virus disease 2019 outbreak. Panminerva Med. 2020, 62, 73–74. [CrossRef] [PubMed]
5. Forni, G.; Mantovani, A. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ. 2021, 28, 626–639. [CrossRef] [PubMed]
6. Rossi, G.A.; Sacco, O.; Mancino, E.; Cristiani, L.; Midulla, F. Differences and similarities between SARS-CoV and SARS-CoV-2: Spike receptor-binding domain infection and host cell infection with support of cellular serine proteases. Infection 2020, 48, 665–669. [CrossRef]
7. Karikó, K.; Muramatsu, H.; Welsh, F.A.; Ludwig, J.; Kato, H.; Akira, S.; Weissman, D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 2008, 16, 1833–1840. [CrossRef]
8. Pollard, A.J.; Bijker, E.M. A guide to vaccinology: From basic principles to new developments. Nat. Rev. Immunol. 2021, 21, 83–100. [CrossRef]
9. Roldão, A.; Mellado, M.C.; Castilho, L.R.; Carrondo, M.J.; Alves, P.M. Virus-like particles in vaccine development. Expert Rev. Vaccines 2010, 9, 1149–1176. [CrossRef]

10. Kyriakidis, N.C.; López-Cortés, A.; González, E.V.; Grimaldos, A.B.; Prado, E.O. SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ Vaccines 2021, 6, 28. [CrossRef]

11. Urbiztondo, L.; Borras, E.; Mirada, G. Vacunas contra el coronavirus. Vacunas 2020, 21, 69–72. [CrossRef]

12. Acosta Altamirano, G.; Frias De Leon, M.G.; Reyes Acosta, M.R.; Torres Estrella, C.U.; Reyes Monte, M.R. Respuesta inmunitaria a COVID-19 y vacunas—Cap. 20. In Estrategias del HRAEI ante el reto de COVID-19; Acosta Altamirano, G., Camacho Oliveras, G., Carrasco Valdez, M., Robledo Cayetano, M., Eds.; Editorial HRAEI Ixtapaluca: Mexico City, Mexico, 2021; pp. 240–246. ISBN 978-607-99330-1-2.

13. Hotez, P.J.; Corry, D.B.; Strych, U.; Bottazzi, M.E. COVID-19 vaccines: Neutralizing antibodies and the alum advantage. Nat. Rev. Immunol. 2020, 20, 399–400. [CrossRef] [PubMed]

14. Magnussen, S.E.; Altenburg, A.F.; Bengtsson, K.L.; Bosman, F.; de Vries, R.D.; Rimmelzaan, G.F.; Stertman, L. Matrix-MTM adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol. Res. 2018, 66, 224–233. [CrossRef] [PubMed]

15. Tian, J.H.; Patel, N.; Haupt, R.; Zhou, H.; Weston, S.; Hammond, H.; Logue, J.; Portnoff, A.D.; Norton, J.; Guebre-Xabier, M.; et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 2021, 12, 3755. [CrossRef]

16. Francica, J.R.; Flynn, B.J.; Foulds, K.E.; Noe, A.T.; Werner, A.P.; Moore, I.N.; Gagne, M.; Johnston, T.S.; Tucker, C.; Davis, R.L.; et al. Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibody and T Cell Response Against Virus Challenge in Nonhuman Primates. bioRxiv 2021. [CrossRef]

17. Watterson, D.; Wijesundara, D.K.; Modhiran, N.; Mordant, F.L.; Li, Z.; Avumegah, M.S.; McMillan, C.L.; Lackenby, J.; Guilfoyle, K.; van Amerongen, G.; et al. Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clin. Transl. Immunol. Res. 2021, 10, e1269. [CrossRef]

18. Bevington, S.L.; Cauchy, P.; Withers, D.R.; Lane, P.J.; Cockerill, P.N. T cell receptor and cytokine signaling can function at different stages to establish and maintain transcriptional memory and enable T helper cell differentiation. Front. Immunol. 2017, 8, 204. [CrossRef]

19. COVID-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ 2021, 372. [CrossRef] [PubMed]

20. Polack, P.F.; Thomas, S.J.; Kitchin, N.; Absalon, J.;urtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Mooreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [CrossRef] [PubMed]

21. Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Candidates. Available online: https://www.pfizer.com/news/release/press-release-detail/pfizer-and-biontech-initiate-study-part-broad-development (accessed on 25 February 2021).

22. The First Interim Data Analysis of the Sputnik V Vaccine against COVID-19 Phase III Clinical Trials in the Russian Federation Demonstrated 92% Efficacy. Available online: https://www.businesswire.com/news/home/20201110005675/en/The-First-Interim-Data-Analysis-of-the-Sputnik-V-Vaccine-Against-COVID-19-Phase-III-Clinical-Trials-in-the-Russian-Federation-Demonstrated-92-Efficacy (accessed on 18 May 2021).

23. Sahin, U.; Meik, A.; Derhovanessian, E.; Vogler, I.; Kranz, L.M.; Vormehr, M.; Baum, A.; Pascal, K.; Quadt, J.; Maurus, D.; et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020, 586, 594–599. [CrossRef]

24. Wu, S.; Zhong, G.; Zhang, J.; Shuai, L.; Zhang, Z.; Wen, Z.; Wang, B.; Zhao, Z.; Song, X.; Chen, Y.; et al. A single dose of an adenovirus-vector vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 2020, 11, 4081. [CrossRef] [PubMed]

25. Voysey, M.; Costa Clemens, S.A.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet 2021, 397, 881–891. [CrossRef]

26. Stephenson, K.E.; Le Gars, M.; Sadoff, J.; De Groot, A.M.; Heerwegh, D.; Truyers, C.; Attyeo, C.; Loos, C.; Chandrashekar, A.; McMahan, K.; et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA 2021, 325, 1535–1544. [CrossRef]
32. Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V.; Tukhvatulin, A.I.; Zubkova, O.V.; Dzhurullueva, A.S.; Kovyrshina, A.V.; Lubenets, N.L.; Grousse, D.M.; Erokhova, A.S.; et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised con-trolled phase 3 trial in Russia. *Lancet* 2021, 397, 671–681. [CrossRef]

33. Zhu, F.C.; Guan, X.H.; Li, Y.H.; Huang, J.Y.; Jiang, T.; Hou, L.H.; Li, J.X.; Yang, B.F.; Wang, L.; Wang, W.J.; et al. Immunogenicity and safety of a recombinant adenosine type-5-vectorized COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* 2020, 396, 479–488. [CrossRef]

34. Zhang, Y.; Zeng, G.; Fan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang, R.; Yin, W.; et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A ran-domized, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect. Dis.* 2021, 21, 181–192. [CrossRef]

35. Bharat Biotech and ICMR Announce Interim Results from Phase 3 Trials of COVAXIN®. Demonstrate Overall Interim Clinical Efficacy of 78% and 100% Efficacy against Severe COVID-19 Disease. Available online: https://www.bharatbiotech.com/images/press/covaxin-phase3-clinical-trials-interim-results.pdf (accessed on 1 May 2021).

36. Ella, R.; Vadrevu, K.M.; Jogan, H.; Prasad, S.; Reddy, S.; Sarangi, V.; Ganneru, B.; Sapkal, G.; Yadav, P.; Abraham, P.; et al. Safety and immunogenicity of an Inactivated SARS-CoV-2 vaccine, BBV152: A Double-blind, randomised, phase 1 trial. *Lancet Infect. Dis.* 2021, 21, 637–646. [CrossRef]

37. Explicación de la Autorización de Uso de Emergencia para las Vacunas. Available online: https://www.fda.gov/vaccines-blood-biologics/vaccines-explicacion-de-la-autorizacion-de-uso-de-emergencia-para-las-vacunas (accessed on 20 March 2021).

38. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine. Available online: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine (accessed on 6 February 2022).

39. Spikevax and Moderna COVID-19 Vaccine. Available online: fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine (accessed on 6 February 2022).

40. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 Subcomittee on Safety Signals Related to the AstraZeneca COVID-19 Vaccine. Available online: https://www.who.int/news/item/19-03-2021-statement-of-the-who-global-advisory-committee-on-vaccine-safety-(gacvs)-covid-19-subcommittee-on-safety-signals-related-to-the-astrazeneca-covid-19-vaccine (accessed on 20 March 2021).

41. Coronavirus Vaccine Tracker. Available online: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html (accessed on 15 April 2021).

42. Owen, J.A.; Punt, J.; Stratford, S.A. (Eds.) *Kuby Immunology*, 7th ed.; W. H. Freeman and Company: New York, NY, USA, 2014; Volume 148, pp. 148–162.

43. Kaul, D.; Ogra, P.L. Mucosal responses to parenteral and mucosal vaccines. *Dev. Biol. Stand.* 1998, 95, 141–146. [PubMed]

44. Johns Hopkins. Booster Shots, Third Dose and Additional Doses for COVID-19 Vaccines—What You Need to Know. Available online: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/booster-shots-and-third-doses-for-covid-19-vaccines-what-you-need-to-know (accessed on 20 February 2022).

45. Centers for Disease Control and Prevention (CDC). Effectiveness of a Third Dose of mRNA Vaccines against COVID-19-Related Disease. Available online: https://www.cdc.gov/mmwr/nn/Volume71/wr/mm7104e3.htm?s_cid=mm7104e3_w (accessed on 20 February 2022).

46. Müller, M.; Volzke, J.; Subin, B.; Müller, S.; Sombetzki, M.; Reisinger, E.C.; Müller-Hilke, B. Single-boost COVID-19 vaccine: An interim analysis of a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect. Dis.* 2021, 21, 181–192. [CrossRef]

47. He, Q.; Mao, Q.; An, C.; Zhang, J.; Gao, F.; Bian, L.; Li, C.; Liang, Z.; Xu, M.; Wang, J. Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates. *Emerg Microbes Infect.* 2021, 10, 629–637. [CrossRef] [PubMed]

48. Hillus, D.; Schwarz, T.; Tober-Lau, P.; Vanshylla, K.; Hastor, H.; Thibeault, C.; Jentzsch, S.; Helbig, E.T.; Lippert, L.J.; Tscheak, P.; et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study. *Lancet Respir. Med.* 2021, 9, 1255–1265. [CrossRef]

49. Eroglu, B.; Nuwarda, R.F.; Ramzan, I.; Kayser, V. A Narrative Review of COVID-19 Vaccines. *Vaccines* 2022, 10, 62. [CrossRef]

50. Vacunas e Inmunización: Qué es la Vacunación? Available online: https://www.who.int/es/news-room/q-a-detail/vaccines-and-immunization-what-is-vaccination (accessed on 15 April 2021).

51. Clements, J.D.; Freytag, L.C. Parenteral vaccination can be an effective means of inducing protective mucosal responses. *Clin. Vaccine Immunol.* 2016, 23, 438–441. [CrossRef]

52. Ketia, T.J.; Chaturbhuj, D.; Cruz-Portillo, V.M.; Francomano, E.; Golden, E.; Chandrasekhar, S.; Debnath, G.; Diaz-Tapia, R.; Yasmeen, A.; Leconet, W.; et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. *bioRxiv* 2021. [CrossRef]

53. Shimabukuro, T.T.; Kim, S.Y.; Myers, T.R.; Moro, P.L.; Oduyebo, T.; Panagiotakopoulos, L.; Marquez, P.L.; Olson, C.K.; Liu, R.; Chang, K.T.; et al. Preliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons. *N. Engl. J. Med.* 2021, 384, 2273–2282. [CrossRef]
54. COVID-19 Vaccination—Clinical Care. Available online: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fclinical-considerations.html (accessed on 12 April 2021).

55. Whitaker, J.A.; Valles, K.; Tosh, P.K.; Poland, G.A. Vaccine use in immunocompromised adults. In Vaccinations; Elsevier Inc.: Amsterdam, The Netherlands, 2019; pp. 139–162. [CrossRef]

56. Yau, K.T.; Chan, C.T.; Abe, K.; Jiang, Y.; Atiquzzaman, M.I.; Mullin, S.; Shadowitz, E.; Liu, L.; Kostadinovic, E.; Sukovic, T.; et al. Differences in Mrna-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ 2022, 194, E297–E305. [CrossRef]

57. Callaway, E. Coronavirus variants get Greek names—But will scientists use them? Nature 2021, 594, 162. [CrossRef]

58. Madhi, S.A.; Baillie, V.; Cutland, C.L.; Voysey, M.; Koen, A.L.; Fairlie, L.; Padayachee, S.D.; Dheda, K.; Barnabas, S.L.; Bhorat, Q.E.; et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 2021, 384, 1885–1898. [CrossRef]

59. Abu-Raddad, L.J.; Chemaitelly, H.; Butt, A.A.; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 COVID-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N. Engl. J. Med. 2021, 385, 187–189. [CrossRef] [PubMed]

60. Moyo-Gwete, T.; Madzivhandila, M.; Makhado, Z.; Ayres, F.; Mhlanga, D.; Oosthuysen, B.; Lambson, B.E.; Kagudi, P.; Tegally, H.; Iranzadeh, A.; et al. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N. Engl. J. Med. 2021, 384, 2161–2163. [CrossRef] [PubMed]

61. Stamatatos, L.; Czartoski, J.; Wan, Y.H.; Homad, L.J.; Rubin, V.; Glantz, H.; Neradilek, M.; Seydoux, E.; Jennewein, M.F.; MacCamy, A.J.; et al. mRNA vaccine vaccination cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 2021, 372, 1413–1418. [CrossRef]

62. Goel, R.R.; Apostolidis, S.A.; Painter, M.M.; Mathew, D.; Pattekar, A.; Kuthuru, O.; Gouma, S.; Hicks, P.; Meng, W.; Rosenfeld, A.M.; et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci. Immunol. 2021, 6, eabf6950. [CrossRef] [PubMed]

63. Urbanowicz, R.A.; Tisolerdis, T.; Jackson, H.J.; Cusin, L.; Duncan, J.D.; Chappell, J.G.; Tarr, A.W.; Nightingale, J.; Norrish, A.R.; Ikram, A.; et al. Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Sci. Transl. Med. 2021, 13, eabj0847. [CrossRef]

64. Crotty, S. Hybrid immunity. Science 2021, 372, 1392–1393. [CrossRef]

65. Wang, Z.; Muecksf, F.; Schaefer-Babajew, D.; Finkin, S.; Iman, V.; Gaebler, C.; Hoffmann, H.H.; Barnes, C.O.; Cipolla, M.; Ramos, V.; et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021, 595, 426–431. [CrossRef]

66. Reynolds, C.J.; Pade, C.; Gibbons, J.M.; Butler, D.K.; Otter, A.D.; Menacho, K.; Fontana, M.; Smit, A.; Sackville-West, J.E.; Cutino-Moguel, T.; et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science 2021, 372, 1418–1423. [CrossRef]

67. Andreano, E.; Paciello, I.; Piccini, G.; Manganaro, N.; Pileri, P.; Hyseni, M.; Leonardi, M.; Pantano, E.; Abbiento, V.; Benincasa, L.; et al. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature 2021, 600, 530–535. [CrossRef]

68. Andreano, E.; Rappuoli, R. Immunodominant antibody germlines in COVID-19. J. Exp. Med. 2021, 218, e20210281. [CrossRef] [PubMed]

69. Su, F.; Patel, G.B.; Hu, S.; Chen, W. Induction of mucosal immunity through systemic immunization: Phantom or reality? Hum. Vaccin. Immunother. 2016, 12, 1070–1079. [CrossRef] [PubMed]

70. Sierra-Martinez, S.; Cruz-Zarate, D.; Rodriguez-Cornejo, E.R.; Macias-Kauffer, L.R.; Reyes-Montes, M.R.; Acosta-Altamirano, G. Use of a Non-Invasive Method for Detection of nasal and Pharyngeal Neu-tralizing Antibodies in Immunized Patients against Sars-CoV-2. Immunol. Res. Ther. J. 2021, 3, 120. [CrossRef]

71. Travis, C.R. As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Ad-ministration for COVID-19 Disease Prevention. Front. Immunol. 2020, 11, 591897. [CrossRef]

72. Ejemel, M.; Li, Q.; Hou, S.; Schiller, Z.; Wallace, A.; Amcheslavsky, A.; Yilmaz, N.K.; Toomey, J.; Schneider, R.; Close, B.; et al. IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity. bioRxiv 2020. [CrossRef]

73. México Tiene la Mayor Letalidad por COVID-19 Entre las 20 Naciones más Afectadas, Según la Universidad Johns Hopkins. Available online: https://cnnspanol.cnn.com/2021/02/10/mexico-tiene-la-mayor-letalidad-por-covid-19-entre-las-20-naciones-mas-afectadas-segun-la-universidad-johns-hopkins/ (accessed on 6 May 2021).

74. Coronavirus (COVID-19) Vaccinations. Available online: https://ourworldindata.org/covid-vaccinations?country=MEX (accessed on 30 January 2022).

75. BioNTech Starts Vaccine Production at New Site in Germany. Available online: https://www.dw.com/en/biontech-starts-vaccine-production-at-new-site-in-germany/a-56524305 (accessed on 8 May 2021).

76. Secretaría de Relaciones Exteriores: Arriba a México Cargamento con Antigén de Aztra Zeneca para Producción de Vacunas Contra COVID-19. Available online: https://www.gob.mx/salud/prensa/023-arriba-a-mexico-cargamento-con-antigeno-de-aztrazeneca-para-produccion-de-vacuna-contra-covid-19 (accessed on 20 January 2021).

77. Secretaría de Relaciones Exteriores: México Recibe 3 Millones de Dosis de la Vacuna Cansino para su Envasado y Proceso Final. Available online: https://www.gob.mx/sre/prensa/mexico-recibe-3-millones-de-dosis-de-la-vacuna-de-can-sino-para-su-envasado-y-proceso-final?idiom=es (accessed on 11 March 2021).
78. Arrecia la Carrera de Mexicanos por el Desarrollo de Vacunas Contra COVID-19. Available online: https://www.conexiones365.com/nota/expo-med/innovacion/vacuna-mexicana-covid19-proyectos (accessed on 1 September 2020).

79. Sun, W.; Leist, S.R.; McCroskery, S.; Liu, Y.; Slamanig, S.; Oliva, J.; Amanat, F.; Schäfer, A.; Dinnon, K.H.; García-Sastre, A.; et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine 2020, 62, 103132. [CrossRef]

80. Avimex®Anuncia el Desarrollo de Patria: Vacuna Mexicana contra SARS-CoV-2. Available online: https://avimex.com.mx/noticias-y-eventos/38 (accessed on 16 May 2021).

81. Zimmermann, P.; Pittet, L.F.; Finn, A.; Pollard, A.J.; Curtis, N. Should children be vaccinated against COVID-19? Arch. Dis. Child. 2022, 107, e1. [CrossRef]

82. Walter, E.B.; Talaat, K.R.; Sabharwal, C.; Gurtman, A.; Lockhart, S.; Paulsen, G.C.; Barnett, E.D.; Muñoz, F.M.; Maldonado, Y.; Pahud, B.A.; et al. Evaluation of the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age. N. Engl. J. Med. 2022, 386, 35–46. [CrossRef]

83. González Farias, A.M.; Martínez Sierra, M.; Sánchez-Conejo, A.R.; González Gozález, T.F.; Juárez García, V.; Acosta-Altamirano, G. Nasal Mask: An alternative to prevent contagion during essential activities. Biomed. J. Sci. Tech. Res. 2021, 34, 27018–27022. [CrossRef]

84. SARS-CoV-2 Virus Mutations & Variants. Available online: https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update47-sars-cov-2-variants.pdf?sfvrsn=f2180835_4 (accessed on 20 May 2021).

85. Gupta, T.; Gupta, S.K. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int. Immunopharmacol. 2020, 86, 106717. [CrossRef]

86. Liang, Z.; Zhu, H.; Wang, X.; Jing, B.; Li, Z.; Xia, X.; Sun, H.; Yang, Y.; Zhang, W.; Shi, L.; et al. Adjuvants for Coronavirus Vaccines. Front. Immunol. 2020, 11, 589633. [CrossRef] [PubMed]

87. Chabeda, A.; Yanez, R.J.R.; Lamprecht, R.; Meyers, A.E.; Rybicki, E.P.; Hitzeroth, I.I. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018, 5, 46–58. [CrossRef] [PubMed]

88. Nova, E.; Montero, S.; Marcos, A. La estrecha relación entre la nutrición y el sistema inmunitario. In Soporte Nutricional en el Paciente Oncológico; Gloss: Madrid, Spain, 2004; pp. 9–21.

89. Calder, P.C. Nutrition, immunity and COVID-19. BMJ Nutr. Prev. Health 2020, 3, 74–92. [CrossRef] [PubMed]

90. Preciado-Ortiz, M.E.; Sánchez-Reyes, K.; Álvarez-Zavala, M.; González-Hernández, L.A.; Ramos-Solano, M.; Andrade-Villanueva, J. Obesidad e infecciones. Rev. Med. 2018, 9, 341–344.

91. Vacunas Contra el COVID-19 | En Qué Consiste la Pugna por las Patentes (y Cuál Puede ser el Riesgo de Liberarlas). Available online: https://www.bbc.com/mundo/noticias-57016980 (accessed on 21 May 2021).